Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451451 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,417
- Enrollment target
NCT00451451 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 1,417 participants.
The verdict
NCT00451451, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,417 participants
- Enrollment target
Study Summary
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse. Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.
Interventions
- DRUG Placebo
- DRUG BG00012
- DRUG Glatiramer Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,417 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451451
The ClinicalTrials.gov registry entry for NCT00451451 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00451451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00451451 about?
NCT00451451 is a clinical study titled "Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis". To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it take...
What is the current status of trial NCT00451451?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,417 participants. The study started on 2007-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00451451?
The interventions under investigation include: Placebo (DRUG), BG00012 (DRUG), Glatiramer Acetate (DRUG).
Who is sponsoring clinical trial NCT00451451?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.